Lagast H, Klastersky J, Standiford H, Viollier A
Infection. 1984 May-Jun;12(3):190-3. doi: 10.1007/BF01640897.
Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperazone alone or in combination with mezlocillin or amikacin to human volunteers. One hour after the infusion, cefoperazone (2 g), cefoperazone + mezlocillin (5 g) and cefoperazone + amikacin (500 mg) achieved comparable activity against Escherichia coli and Klebsiella pneumoniae (100% of the strains being killed by a 1:8 or greater dilution). The activity of the three regimens was also similar against Pseudomonas aeruginosa (87-96% of the sera had an SBA greater than or equal to 1:8) and somewhat less for Staphylococcus aureus (52-60% with SBA greater than or equal to 1:8). Six and ten hours after administration, the SBAs were much lower for all regimens; a small advantage for cefoperazone + mezlocillin against K. pneumoniae could be shown in comparison to the other regimens.
在人类志愿者静脉注射头孢哌酮单独使用或与美洛西林或阿米卡星联合使用后,对血清杀菌活性(SBA)进行了体外研究。输注1小时后,头孢哌酮(2g)、头孢哌酮+美洛西林(5g)和头孢哌酮+阿米卡星(500mg)对大肠杆菌和肺炎克雷伯菌具有相当的活性(100%的菌株在1:8或更高稀释度下被杀死)。这三种方案对铜绿假单胞菌的活性也相似(87-96%的血清SBA大于或等于1:8),对金黄色葡萄球菌的活性略低(52-60%的血清SBA大于或等于1:8)。给药6小时和10小时后,所有方案的SBA都低得多;与其他方案相比,头孢哌酮+美洛西林对肺炎克雷伯菌有轻微优势。